- Home
- BCDA vs WATT Comparison
BCDA vs WATT Comparison
Compare BCDA & WATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- WATT
- Stock Information
- Founded
- BCDA N/A
- WATT 2012
- Country
- BCDA United States
- WATT United States
- Employees
- BCDA N/A
- WATT N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- WATT Radio And Television Broadcasting And Communications Equipment
- Sector
- BCDA Health Care
- WATT Technology
- Exchange
- BCDA Nasdaq
- WATT Nasdaq
- Market Cap
- BCDA 7.9M
- WATT 3.9M
- IPO Year
- BCDA N/A
- WATT 2014
- Fundamental
- Price
- BCDA $2.68
- WATT $0.61
- Analyst Decision
- BCDA Strong Buy
- WATT Strong Buy
- Analyst Count
- BCDA 1
- WATT 2
- Target Price
- BCDA $25.00
- WATT $2.25
- AVG Volume (30 Days)
- BCDA 73.1K
- WATT 132.1K
- Earning Date
- BCDA 11-06-2024
- WATT 11-07-2024
- Dividend Yield
- BCDA N/A
- WATT N/A
- EPS Growth
- BCDA N/A
- WATT N/A
- EPS
- BCDA N/A
- WATT N/A
- Revenue
- BCDA $428,000.00
- WATT $370,184.00
- Revenue This Year
- BCDA $6.92
- WATT $95.75
- Revenue Next Year
- BCDA N/A
- WATT $834.07
- P/E Ratio
- BCDA N/A
- WATT N/A
- Revenue Growth
- BCDA 0.71
- WATT N/A
- 52 Week Low
- BCDA $1.96
- WATT $0.54
- 52 Week High
- BCDA $23.25
- WATT $2.75
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- WATT 47.76
- Support Level
- BCDA $2.39
- WATT $0.56
- Resistance Level
- BCDA $2.90
- WATT $0.61
- Average True Range (ATR)
- BCDA 0.18
- WATT 0.04
- MACD
- BCDA -0.00
- WATT 0.01
- Stochastic Oscillator
- BCDA 53.70
- WATT 67.60
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.